NEWSROOM

BSEM

BioStem Technologies Expands Partnership with the Florida Panthers as a Sponsor for the 13th Season of the “Heroes Among Us” Program

BioStem Technologies Expands Partnership with the Florida Panthers as a Sponsor for the 13th Season of the “Heroes Among Us” Program

Oct 2, 2025

Program has honored more than 500 members of the military since its inception Sponsorship honors both local military veterans and healthcare professionals POMPANO BEACH, Fla., October 2, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, and the Florida Panthers, announced today that...

BioStem Technologies Expands Partnership with the Florida Panthers as a Sponsor for the 13th Season of the “Heroes Among Us” Program

BioStem Technologies (OTC: BSEM) Showcasing its Leading BioREtain®Technology at the Symposium for Advanced Wound Care (SAWC) Fall Meeting

Sep 5, 2025

Company co-exhibiting with strategic partner Venture Medical, LLC, highlighting collaborative innovation in chronic wound care management Three scientific posters feature BioStem’s proprietary allograft portfolio POMPANO BEACH, Fla., Sept. 05, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for...

BioStem Technologies Expands Partnership with the Florida Panthers as a Sponsor for the 13th Season of the “Heroes Among Us” Program

BioStem Technologies to Present at Two Upcoming Investor Conferences

Sep 2, 2025

POMPANO BEACH, Fla., Sept. 02, 2025 - PRISM MediaWire - Press Release Service - Press Release Distribution - BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, today announced that Company management will present at the following upcoming investor conferences being held in New York, NY. Morgan Stanley Global Healthcare Conference: Format: Fireside Chat Date:...

BioStem Technologies Expands Partnership with the Florida Panthers as a Sponsor for the 13th Season of the “Heroes Among Us” Program

BioStem Technologies Announces Insider Share Purchase by Chairman and Chief Executive Officer

Aug 21, 2025

POMPANO BEACH, FL, August 21, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, discloses an insider purchase of common stock from Jason Matuszewski, Chairman and Chief Executive Officer of BioStem Technologies. Mr. Matuszewski purchased a total of 15,500 shares on August 19, 2025, totaling approximately $100,000. The purchases were...

BioStem Technologies Expands Partnership with the Florida Panthers as a Sponsor for the 13th Season of the “Heroes Among Us” Program

BioStem Technologies Reports Preliminary Second Quarter 2025 Financial Results

Aug 14, 2025

POMPANO BEACH, FL, August 14, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (“BioStem” or the “Company”) (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today reported preliminary financial results for the second quarter ended June 30, 2025. Recent Business Highlights: Appointed Brandon Poe as Chief Financial Officer, a seasoned financial executive with experience across the...

BioStem Technologies Expands Partnership with the Florida Panthers as a Sponsor for the 13th Season of the “Heroes Among Us” Program

BioStem Technologies Appoints Brandon Poe as Chief Financial Officer

Aug 14, 2025

Seasoned healthcare CFO with senior experience in capital markets and financial operations across private and publicly traded companies to lead BioStem’s financial team POMPANO BEACH, FL, August 14, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (“BioStem” or the “Company”) (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced the appointment of Brandon Poe as its Chief...

BioStem Technologies Expands Partnership with the Florida Panthers as a Sponsor for the 13th Season of the “Heroes Among Us” Program

BioStem Technologies to Host Second Quarter 2025 Financial Results Conference Call on August 14, 2025

Jul 30, 2025

Conference call and webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., July 29, 2025 - PRISM MediaWire - BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived products for advanced wound care, announces it will release its second quarter 2025 financial results on Thursday, August 14, 2025, and host a conference call and webcast at 4:30 PM ET. The webcast will feature a review of second quarter...

BioStem Technologies Expands Partnership with the Florida Panthers as a Sponsor for the 13th Season of the “Heroes Among Us” Program

BioStem Technologies Provides Comments on CMS CY 2026 Proposed Medicare Reimbursement Rule Changes for Skin Substitutes

Jul 17, 2025

The Company welcomes CMS’ efforts to reform skin substitute payment policy and will continue to engage with CMS and other stakeholders to optimize the proposed changes POMPANO BEACH, Fla., July 17, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, comments on the Centers for Medicare and Medicaid Services (“CMS”) release of the...

BioStem Technologies Expands Partnership with the Florida Panthers as a Sponsor for the 13th Season of the “Heroes Among Us” Program

BioStem Technologies to Present at the Advanced Wound Care Summit in Boston on July 15, 2025, at 2:00 PM ET

Jul 10, 2025

Jason Matuszewski, Chairman and CEO, to present BioStem’s current position in the chronic wound care market and key opportunities for growth POMPANO BEACH, Fla., July 10, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that Jason Matuszewski, the Company’s Chairman and CEO, will present at the Advanced Wound Care...

BioStem Technologies Expands Partnership with the Florida Panthers as a Sponsor for the 13th Season of the “Heroes Among Us” Program

BioStem Technologies Completes Enrollment in Clinical Trial Evaluating BioREtain® Amnion Chorion for Treatment of Diabetic Foot Ulcers

Jun 23, 2025

Head-to-head study comparing BioREtain®- processed Amnion Chorion (BR-AC) allograft to standard of care initiated in Q4 2024 to demonstrate healing superiority Topline results and full data analysis expected in Q4 2025 POMPANO BEACH, Fla., June 23, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (“BioStem” or the “Company”) (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today...

BioStem Technologies Expands Partnership with the Florida Panthers as a Sponsor for the 13th Season of the “Heroes Among Us” Program

Ernst & Young LLP (EY US) Announces Jason Matuszewski, CEO of BioStem Technologies, as an Entrepreneur Of The Year® 2025 Florida Award Winner

Jun 17, 2025

Award celebrates bold leaders shaping the future through the world’s most ground-breaking companies POMPANO BEACH, Fla., June 17, 2025 - PRISM MediaWire - Ernst & Young LLP (EY US) announced that Jason Matuszewski, CEO and Chairman of the Board of BioStem Technologies (OTC: BSEM), was named an Entrepreneur Of The Year 2025 Florida Award winner. Entrepreneur Of The Year is the preeminent competitive awards program for entrepreneurs and leaders of high-growth companies. For 40 years, EY US...

BioStem Technologies Provides Update on the Company’s Form 10 Submission and SEC Review Process

BioStem Technologies Provides Update on the Company’s Form 10 Submission and SEC Review Process

Jun 3, 2025

Upon SEC approval of the amended Form 10, BioStem expects to advance its uplisting to Nasdaq POMPANO BEACH, Fla., June 3, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (“BioStem” or the “Company”) (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today provides an update on the Company’s Form 10 registration statement and SEC review process. BioStem believes it has favorably...

BioStem Technologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

BioStem Technologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

May 29, 2025

POMPANO BEACH, Fla., May 29, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that the company will participate in the Goldman Sachs 46th Annual Global Healthcare Conference, which is taking place in Miami. Jason Matuszewski, the Company’s CEO, will participate in a fireside chat and will be available for...

BioStem Technologies Provides Update on the Company’s Form 10 Submission and SEC Review Process

BioStem Announces Notice of Allowance for Three New U.S. Patent Applications

May 28, 2025

Expanding patent portfolio reinforces the Company’s commitment to wound care innovation, with 55 issued patents and 52 pending applications POMPANO BEACH, Fla., May 28, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance...

BioStem Technologies Provides Update on the Company’s Form 10 Submission and SEC Review Process

Ernst & Young (EY) US Announces Jason Matuszewski, CEO of BioStem Technologies, as an Entrepreneur Of The Year® 2025 Florida Award finalist

May 22, 2025

Entrepreneur Of The Year celebrates ambitious entrepreneurs who are shaping the future POMPANO BEACH, Fla., May 22, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM) (the “Company” or “BioStem”), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that Jason Matuszewski, CEO of BioStem is an Ernst & Young LLP (EY US) finalist for the prestigious Entrepreneur...

BioStem Technologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

BioStem Technologies Reports Preliminary First Quarter 2025 Operating and Financial Results

May 12, 2025

Preliminary net revenue increased 73% to $72.5 million for Q1 2025, compared to $41.9 million in Q1 2024 Achieved preliminary GAAP net income of $4.5 million, or $0.27 per share Reported preliminary Q1 2025 Adjusted EBITDA of $7.8 million Quarter-end cash balance of $26.7 million, up from $22.8 million as of December 31, 2024 Financial results conference call and webcast to be held on May 12, 2025 at 4:30 pm ET POMPANO BEACH, FL, May 12, 2025 - PRISM MediaWire - BioStem Technologies, Inc....

BioStem Technologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

BioStem to Showcase its Leading BioREtain® Technology at the Symposium for Advanced Wound Care (SAWC) Spring Meeting

May 1, 2025

Company to co-exhibit with strategic partner Venture Medical, LLC, highlighting collaborative innovation in chronic wound care management Three accepted scientific posters will feature BioStem’s advanced allograft portfolio POMPANO BEACH, Fla., May 1, 2025 - PRiSM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced its agenda for the...

BioStem Technologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

BioStem Technologies to Host First Quarter 2025 Financial Results Conference Call on May 12, 2025

Apr 30, 2025

Conference call and webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., April 30, 2025 - PRISM MediaWire - BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, announces it will release its first quarter 2025 financial results on Monday, May 12, 2025, and will host a conference call and webcast at 4:30 PM ET. The webcast will feature an overview of the...

BioStem Technologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

BioStem Technologies to Present at the Centri Capital Conference

Apr 21, 2025

The presentation will be webcast at 10:30 AM ET on April 22, 2025 POMPANO BEACH, Fla., April 21, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, is pleased to announce that its Chief Executive Officer, Jason Matuszewski, will be presenting and holding one-on-one meetings at the upcoming Centri Capital...

BioStem Technologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

BioStem Technologies Reports Record Preliminary Fourth-Quarter Net Revenue of $102.9 Million and Preliminary Full-Year 2024 Revenue of $301.8 Million

Apr 14, 2025

Company reports record preliminary fourth quarter net revenue of $102.9 Million, contributing to a total of $301.8 Million in revenue for 2024 Achieves preliminary GAAP net income of $15.5 million, or $0.94 per share, marking the fourth consecutive quarter of profitability Preliminary Q4 2024 Adjusted EBITDA of $11.1 Million Financial Results Conference Call and Webcast to be held on April 14, 2025 at 4:30 pm ET POMPANO BEACH, FL, April 14, 2025 - PRISM MediaWire - BioStem Technologies, Inc....

BioStem Technologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

BioStem Technologies to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on April 14, 2025

Apr 8, 2025

Conference Call and Webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., April 08, 2025 - PRISM MediaWire - BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, announces that it will release its fourth quarter and full year 2024 financial results on Monday, April 14, 2025, and host a conference call and webcast at 4:30 PM ET. The webcast will feature an overview...

BioStem Technologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

BioStem Technologies Announces Extension to File 2024 Annual Report with OTC

Apr 1, 2025

POMPANO BEACH, Fla., April 1, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company specializing in the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces it has filed for an extension to submit its annual report for the year ended December 31, 2024 to the OTC The company is currently undergoing a mandatory Securities Exchange Commission (SEC) review process related to its Form 10 registration...

BioStem Technologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

BioStem Announces Notice of Allowance for Two U.S. Patent Applications

Mar 31, 2025

Company continues to innovate and strengthen its patent portfolio with 43 issued patents and 26 pending for its advanced wound care technology POMPANO BEACH, Fla., March 31, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of...

BioStem Technologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

BioStem Technologies to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 27, 2025

The presentation will be webcast at 1:30 PM ET on April 10, 2025 POMPANO BEACH, Fla., March 27, 2025 - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that its Chief Executive Officer, Jason Matuszewski, will present at the 24th Annual Needham Virtual Healthcare Conference at 1:30 PM ET on Thursday, April 10, 2025. Management will also be hosting...

BioStem Technologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

BioStem Receives Institutional Review Board (IRB) Approval to Advance Clinical Trial Demonstrating the Therapeutic Benefits of BioREtain® Technology in Treating Venous Leg Ulcers

Feb 24, 2025

Study comparing BioStem’s proprietary amnion chorion allograft versus the standard of care aims to demonstrate superior outcomes, further validating its clinical efficacy to support market expansion POMPANO BEACH, FL, February 24, 2025 - PRISM MediaWire - BioStem Technologies, Inc. a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces Institutional Review Board (IRB) approval for a clinical...

BioStem Technologies Announces Record Preliminary Fourth Quarter Net Revenue of $102.9 Million, with Full-Year 2024 Net Revenue Expected to Reach $301.8 Million

BioStem Technologies Announces Record Preliminary Fourth Quarter Net Revenue of $102.9 Million, with Full-Year 2024 Net Revenue Expected to Reach $301.8 Million

Jan 13, 2025

POMPANO BEACH, Fla., January 13, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM) (“BioStem”, “we”, “us”, or “our”), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced selected preliminary financial results for the fiscal fourth quarter and full year ended December 31, 2024. 2024 Preliminary Fourth Quarter and Year End Results: Fourth quarter net revenue is expected to...

BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®

BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®

Jan 8, 2025

Study of Vendaje® versus standard of care aims to show superior wound treatment, supporting market expansion POMPANO BEACH, Fla., January 8, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces the initiation of the BR-AM-DFU (BioREtain® Amniotic Membrane - Diabetic Foot Ulcers) clinical trial to evaluate Vendaje® versus...

BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®

BioStem Technologies CEO to Present at Biotech Showcase 2025

Jan 2, 2025

Presentation to be webcast at 2:30 PM PT on Monday, January 13, 2025 POMPANO BEACH, Florida, January 2, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that Jason Matuszewski, the Company’s Chief Executive Officer, will present a corporate overview and update at the Biotech Showcase 2025 conference, which is...

BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®

BioStem Announces Notice of Allowance for U.S. Patent Application for Sterile Human Placental Allografts

Nov 25, 2024

Company continues to advance its placental-derived product portfolio with the first patent granted in the fenestrated wound care market POMPANO BEACH, Fla., Nov. 25, 2024 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for...

BioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare Global

BioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare Global

Nov 20, 2024

Additions of ProgenaMatrix®and revyve™ Antimicrobial Wound Gel part of planned expansion of BioStem’s commercial product portfolio POMPANO BEACH, Fla., November 20, 2024 - PRISM MediaWire - BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics, today announced the signing of a Letter of Intent (LOI) to acquire commercial-stage products and development technologies from ProgenaCare Global...